FDA OKs New Non-Statin, LDL-C Lowering Treatment
|
Bempedoic acid (Nexletol, Esperion) is a new lipid-lowering therapy option for patients with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease
|
Read more
|
ADVERTISEMENT
|
|
|